NEW YORK (GenomeWeb News) – The Foundation for the National Institutes of Health on Thursday announced that the I-SPY 2 Trial has graduated the first two drugs from its multidrug standing platform trial.
The two drugs are veliparib, developed by AbbVie, and neratinib, developed by Puma Biotechnology. Both are for breast cancer.
I-SPY 2 is a five-year, $27 million cancer trial launched in 2010 to screen new breast cancer drugs, using genetic and other biomarkers. The program is sponsored by the QuantumLeap Healthcare Collaborative, a non-profit foundation and a co-project manager of I-SPY 2.
Short for Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis, I-SPY 2 is managed by the Biomarkers Consortium, a collaboration between the Foundation for the National Institutes of Health, the NIH, the US Food and Drug Administration, and biopharmaceutical firms.
"The I-SPY 2 trial is among our most ambitious partnership projects," FNIH President and Executive Director Maria Freire said in a statement. "This first success reinforces the collaborative approach spearheaded by the Biomarkers Consortium as a model for research among scientists and the pharmaceutical industry to help speed the development of medicines and therapies and improve patient care."